13F Data
13F filer · CIK 1746488

Ponoi II Management, LLC

San Francisco, CA · filing since Q4 2020 · last filing Nov 14, 2022
Reported value
$38.3M
+$1.5M vs prior
Positions
4
New / sold out
0 / 0
Added / reduced
0 / 0
Turnover
0.0%
buys $0 · sells $0
Top-10 weight
100.0%

Biggest buys vs Q2 2022

No new or increased positions this quarter.

Biggest sells vs Q2 2022

No reduced or sold positions this quarter.

Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.

Reported value by quarter

Q4 2020: $137.3MQ1 2021: $130.6MQ2 2021: $123.4MQ3 2021: $67.5MQ4 2021: $55.1MQ1 2022: $45.1MQ2 2022: $36.8MQ3 2022: $38.3M
Q4 2020Q3 2022

Holdings · Q3 2022

#SecuritySharesValueWeight
1NGM Biopharmaceuticals IncCOM1,298,908$17.0M44.41%
2Revolution Medicines IncCOM685,011$13.5M35.31%
3Nurix Therapeutics IncCOM327,123$4.3M11.14%
4RAPT Therapeutics IncCOM145,401$3.5M9.14%